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Abstract
In some type of leukemia and sarcoma, cancer development mechanism is straightfor-
ward; aberrant activation of single oncogene transforms cells. Such oncogenes are master 
genes which function upstream of transcriptional cascade. On the other hand, cancer 
genome analyses clearly show that that of common epithelial cancers such as lung adeno-
carcinoma is related to accumulations of mutations in "non-master" oncogenes, leading to 
heterogeneity in aggressiveness and clinical behavior among their patients. Common 
epithelial carcinomas do not arise from mutations in specific oncogenes but from accel-
erated growth rate as a result of summation of growth advantage of each driver mutations 
on a different composition of oncogenes. Because most of human cancers are of epithelial 
origin, this heterogeneity gives us a challenge both in understanding the molecular mecha-
nism of carcinogenesis and in the treatment of  carcinoma. 
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Introduction
 Although 85% of human cancer is derived from 
epithelial cells, which cover the surfaces of skin, 
gut, and other tube structures throughout our 
bodies, most information about cancer and its 
mechanisms were not derived from studying 
cancers of these cells, but rather from less 
common cancers such as leukemia and sarcoma, 
owing to the relatively simple mechanisms of 
leukemogenesis and sarcomagenesis. Leukemia 
and some types of sarcoma are associated with 
the reciprocal chromosomal translocation. Many 
oncogenes have been cloned from the breakpoints 
of these chromosomal translocations. These 
oncogenes are "master  genes that regulate tran-
scription, signal transduction, and cell growth; 
many of them normally mediate developmental 
processes. Whereas activation of  oncogenes,  inac-
tivation of tumor suppressor genes, and formation 
of new fusion proteins are relatively straight-
forward tumorigenic mechanisms in leukemia and 
sarcoma, those of common epithelial cancers are 
caused by accumulations of many types of muta-
tions in "non-master" oncogenes, leading to a wide
diversity of carcinogenic mechanisms, which 
makes them more difficult to identify and clarify.
Burkitt lymphoma
 Burkitt lymphoma is a B-cell malignancy char-
acterized by very aggressive clinical behavior and 
a unique histology, which make its diagnosis rela-
tively easy. It was classified as a special type of 
high-grade non-Hodgkin lymphoma. The molecu-
lar characteristics of Burkitt lymphoma are asso-
ciated with specific reciprocal chromosomal trans-
locations, the most common variant of which is t(8; 
 14)  (q24; q32), which accounts for approximately 
85% of cases and affects genes for c-myc and 
immunoglobulin heavy chain. This chromosomal 
translocation aberrantly activates the c-MYC 
oncogene through the immunoglobulin heavy 
chain enhancer. All Burkitt lymphomas are char-
acterized by disregulated c-MYC genes. How-
ever, v-MYC was initially found in a retrovirus 
that causes avian myelocytomatosis; c-MYC, the 
homologous human sequence, was then identified 
in the specific chromosomal translocation break-
point of Burkitt lymphoma. c-MYC is a tran-
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scription factor that regulates about 15% of all 
human genes. The role of c-MYC as a general 
transcription factor was highlighted when it was 
identified as one of the four gene products 
(Yamanaka factors) that, in combination, could 
reprogram somatic cells into pluripotent stem 
cells (Takahashi et al. 2006). Aberrant c-MYC 
activation results in co-activation of downstream 
genes and changes the fate of once-differentiated 
cells (B cells in case of Burkitt lymphoma), eventu-
ally to permit clonal growth of lymphoma cells. 
Here, the c-MYC oncogene is an example of a 
master gene, which functions upstream in a 
transcriptional cascade and controls expression of 
many downstream genes, aberrant expression of 
which can completely change a cell's fate. Its acti-
vation presents the master gene model of cancer 
development (Rabbitts 2001). In this model, one 
oncogene mutation can lead to a specific type of 
cancer.
T-cell acute lymphoblastic leukemia
 Another example of the master gene model of 
cancer development is the specific chromosomal 
translocation associated with T-cell acute lympho-
blastic leukemia. In this case, the oncogene 
LMO2 is activated by a reciprocal chromosomal 
translocation under the influence of a T-cell recep-
tor  - or a   -chain enhancer. This T cell-specific 
reactivation of master transcriptional regulator 
LMO2 completely changes the T-cell's fate. In 
normal development, LMO2 mediates hemat-
opoietic stem cell development from hemogenic 
endothelial cells in the embryonic dorsal aorta. 
The LMO2 protein is part of a transcription factor 
complex that activates many downstream regula-
tors of hematopoiesis and angiogenesis, including 
c-kit, VE-cadherin, and angiopoietin. LMO2 ex-
pression can trigger blood cell development, and 
thus functions as a master transcriptional regula-
tor of hematopoiesis and angiogenesis. Aberrant 
LMO2 expression in specific T cells endows them 
with a hematopoietic stem cell-like feature: the 
potential of self-replication, through reactivation 
of downstream genes (McCormack et al. 2010, 
Cleveland et al. 2013). The phenomenon of re-
setting through aberrant LMO2 activation was 
recently highlighted in the induction of hemat-
opoietic stem cells (iHSCs) by six genes transfect-
ed into committed lymphoid and myeloid progeni-
tors (Riddle et al. 2014). Thus, a single growth-
increasing mutation in the LMO2 oncogene in T 
cells results in neoplastic transformation of T 
cells, and explains the very aggressive behavior of
T-cell acute lymphoblastic  leukemia. T-cell devel-
opment requires somatic DNA recombination in 
T-cell receptor genes. If these recombination 
errors involve master genes, such as  LMO2, the 
resulting phenotype could be serious. Several 
oncogenes other than LMO2 have been identified 
from breakpoints of specific reciprocal chromo-
somal translocations in leukemia and sarcoma and 
most of them were identified as mediators of the 
transcription factor hierarchy or of the develop-
mental process. In all cases, one mutation in these 
master genes could completely change the cell's 
fate and give it enormous growth advantage. As 
the accumulation of oncogenic mutations is less 
likely in blood cells and mesenchymal cells than 
epithelial cells, more growth-enabling mutations 
on the master genes are needed for cancer de-
velopment in blood and mesenchymal cells. Un-
surprisingly, successful identifications of onco-
genes were achieved through studies of leukemia 
and sarcoma. Burkitt lymphoma is an  aggres-
sive form of B-cell malignancy and T-cell acute 
lymphoblastic leukemia is the T-cell counterpart 
of aggressive leukemia. These two malignancies 
typify the master gene model of cancer develop-
ment.
Myxoid liposarcoma
 Specific chromosomal translocations affect not 
only hematological malignancies but also some 
sarcoma types. One such sarcoma is myxoid 
liposarcoma with a specific chromosomal trans-
location at t(12; 16) (q13; p11). Among four major 
histologically categorized liposarcomas (well dif-
ferentiated, myxoid, round cell, and pleomorphic), 
myxoid liposarcoma is characterized by its unique 
vascular architecture. Its specific chromosomal 
translocation and the resulting FUS-CHOP fusion 
protein primarily instigates sarcoma develop-
ment. FUS-CHOP works within tumors as a 
transcriptional activator. This is another mutated 
master gene model of cancer development.
Heterogeneity in common epithelial carcinoma
 Somatic mutations in so-called oncogenes are 
involved in the development of common epithelial 
carcinomas. However, in this context, oncogenes 
are defined as genes which mutations offer cells a 
growth advantage. Some mutations, for example 
those that truncate C-terminals of the protein 
products, inactivate the coded protein. In these 
cases, the genes are often called tumor suppressor 
genes. However, we do not distinguish tumor
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suppressor genes from oncogenes here. Muta-
tions that confer these growth advantages are 
called driver mutations. Driver mutations are not 
necessarily in the coding region (exome) of the 
oncogenes; frequently, they are found in the pro-
moters and other regulatory sequences, and can 
thus modify the oncogenes' expression levels and 
patterns, and therefore give growth advantages. 
To date, a variety of oncogenes have been identi-
fied though many approaches. They affect cell 
growth, cell cycling, signal transduction, tran-
scription, DNA replication, cell death, and 
apoptosis. Although physiological functions of 
oncogenes vary, they commonly affect the cell 
growth rate. Driver mutations may activate or in-
activate protein product expression; overall, they 
allow cells to grow faster than they normally 
would. In this article, oncogenes are sub-
classified into master genes and non-master 
oncogenes. As mentioned before, master genes 
usually encode transcription factors which work 
on the upstream of transcriptional cascade and 
effect the expression of a number of downstream 
genes. When they are aberrantly expressed or 
activated, they are able to completely change the 
cell fate and eventually give cells enormous 
growth advantage. They normally play a critical 
role in developmental process and decide the cell 
fate. Only one hit on master genes has a potential 
to transform cells. MYC,  LMO2,  TALL ABL and 
 RUNX1 are among master genes. On the other 
hand, non-master oncogenes confer cells relatively 
smaller amount of growth advantage when they 
are mutated and activated compared. They 
usually comprise growth factor receptors (such as 
epidermal growth factor receptor and vascular 
endothelial growth factor receptor) or a member 
of signal transduction pathway. Epithelial cells 
have several distinctive features: their turnover is 
much faster than for other cell types; they 
regenerate from common stem cells and swiftly 
differentiate into various functioning cell types; 
and they divide much faster than other cell types. 
These characteristics of epithelial cells enable or 
force them to accumulate somatic mutations 
within their DNA. As epithelia cover most body 
structure surfaces, they can be exposed to various 
environmental carcinogens (mutagens), such as 
ultraviolet light and cigarette smoke. Thus, the 
simple master-gene model of cancer development 
does not necessarily apply to carcinogenesis 
(development of common epithelial cancers), as 
the single mutated oncogene (master gene) that 
leads to a specific cancer need not occur here. 
Alternatively, acumulation of somatic mutations
on "non-master" oncogenes in different composi-
tion is more likely to be the cause of cancer devel-
opment from epithelium. Of course, the involve-
ment of master gene mutation in carcinogenesis 
not excluded. It is less likely simply because 
master genes comprise only small portion of all 
oncogenes. Therefore, determining the genetic 
basis of each case of carcinogenesis requires com-
prehensive analysis of each cancer genome, which 
has been enabled by recent technological prog-
ress. Actually, major international cancer ge-
nome projects to identify a set of oncogenes 
involved and new oncogenes (if any) are currently 
underway (Lawrence et al. 2013). These analyses 
found no common development pathway to  specif-
ic epithelial carcinoma types; rather, they usually 
found involvement by many non-master 
oncogenes and identified several genes that mu-
tated at significantly high frequencies (Vogelstein 
et al. 2013). In the case of adult, esophageal 
squamous cell carcinoma, about 75 non-
synonymous mutations (mutations that would be 
expected to alter gene products) per tumor were 
found. Although determining which mutations 
are driver mutations for these cancers is difficult 
and most of the mutations are not driver 
mutations, some mutations were in the better-
known oncogenes, such as TP53 or KRAS . The 
presence of strong mutagens drastically increases 
the average number of mutations per tumor. 
Even when each driver mutation's contribution to 
the cell's growth advantage is small, their 
accumulation will turn normal cells into 
carcinoma cells eventually. This pattern may 
confound the chief aim of the cancer genome 
analyses, i. e., discovery of new oncogenes. 
Although oncogenes that harbor small driver 
mutations might be identified, their individual 
contributions to the cell's growth advantage could 
not be as great as those of master gene mutations.
Between " reactive"  and" neoplastic"
 Current concepts of carcinogenesis clearly dis-
tinguish between reactive processes and neo-
plastic disease. Hepatocellular carcinoma may 
develop from infection by hepatitis B or C virus , 
and be preceded by chronic hepatitis from virus 
infection and resulting liver cirrhosis. As hepat-
ocytes are repeatedly regenerated in association 
with the chronic inflammation, they accumulate 
somatic mutations on oncogenes more frequently 
than do normal liver cells; when accumulation of 
driver mutations reaches a certain level, the cells 
undergo a neoplastic change. In this scenario, the
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reactive process is continuous with the neoplastic 
process. The cancer genome atlas shows about 
40 non-synonymous mutations per hepatocellular 
 carcinoma. Although identifying the final muta-
tion that transformed the reactive process to the 
neoplastic one is unlikely, accumulation of small 
contributions to cell growth ultimately leads to 
the liver malignancy. Carcinogenic processes are 
closely connected to recurrent regeneration trig-
gered by chronic inflammation. The near future 
may bring genome analysis of chronic inflamma-
tory diseases that lead to carcinogenesis, uch as 
liver cirrhosis, metaplastic gastritis (Helicobacter 
 pylori infection to gastric adenocarcinoma), and 
chronic gingivitis (oral cavity inflammation to 
squamous cell carcinoma). The distinction be-
tween reactive process and neoplastic disease 
may be less clear in the genome context, just as 
molecular distinctions between benign and 
malignant tumors became less clear in studies of 
stepwise colorectal carcinogenesis.
Grade, aggressiveness, and cancer genomics
 Cancers caused by the aberrant expression of 
master genes usually behave uniformly, depend-
ing on the clinical entity. For example, the clinical 
course and behavior of Burkitt lymphoma is 
uniform among its patients. Chronic myeloid 
leukemia, another master gene disease based on 
the BCR-ABL mutation, showed an almost 
identical phenotype in its chronic phase. The 
reason for their uniformity lies in the influence of 
the master gene mutation on the etiology of 
diseases (which, in this context, includes aberrant 
expression by chromosomal translocation). This 
feature allows these cancers to be similarly 
treated. In contrast, clinical manifestations of 
gastric carcinoma vary among patients. Some 
very well differentiated adenocarcinomas of the 
stomach were once classified as gastric adenomas 
and behave almost as benign tumors; partial 
mucosal resections can completely cure such 
cases. Much more aggressive forms of gastric 
carcinoma invade the stomach wall deeply and 
metastasize very quickly. Thus, gastric adeno-
carcinoma encompasses a variety of tumors with 
a wide range of malignancy and aggressiveness. 
Structural information (structural atypism) based 
on histological findings is integrated in sub-
classification of stomach adenocarcinoma, then 
further classified into well, moderately, or poorly 
differentiated adenocarcinoma. Although poorly 
differentiated adenocarcinomas are generally 
more aggressive than well differentiated ones,
this tendency depends on the case. In other forms 
of carcinoma, such as endometrial adenocarcino-
ma, a sub-classification grading system is applied 
to endometrioid adenocarcinoma. If the propor-
tion of the adenocarcinoma that shows solid 
growth (i. e., has little tendency to form glands) 
exceeds 50%, the carcinoma is considered to be 
grade 3, and is generally more aggressive than its 
grade 1 counterpart, which would be better 
differentiated (i. e., capable of forming glands). 
Cellular atypism (enlargement of nucleus, uni-
formity of nuclei size within tumor, high N/C 
ratio, prominent mitosis counts, and nucleoli) is of 
higher value in subclassifying transitional cell 
carcinoma of the urinary bladder. Grade 3 transi-
tional cell carcinoma shows marked cellular 
atypism and is generally more malignant than 
grade 1 tumors. All these sub-classifications 
should be considered in their treatment because 
of the wide clinical variety of common epithelial 
carcinomas. Genome analysis of common epitheli-
al carcinomas gives a rationale for this clinical 
variety. Gastric cancers have a median of 53 non-
synonymous mutations per tumor; endometrial 
cancers have 49. The cancer phenotype is the 
result of accumulation of relatively small driver 
mutations on non-master oncogenes; it represents 
the summation of the growth advantage con-
ferred on the tumor by each driver mutation. The 
amount of growth advantage of each driver 
mutation varies, depending on which gene was 
mutated and the mutation type and site. If the 
mutation is within the activating sites of the 
master genes, its impact on the cell's growth ad-
vantage is enormous, although as driver muta-
tions on non-master oncogenes accumulate to a 
certain level, the degree of growth advantage 
becomes strong enough to transform cells. The 
features of epithelial cells, as discussed before, 
permit such accumulation. Because the simple 
master gene model of cancer development does 
not apply to most carcinogenesis, their aggres-
siveness varies according to the total growth 
advantage from all the mutations. When the 
growth advantage that each driver mutation con-
tributes can be calculated and handled quantita-
tively, a cancer genome atlas of each patient can 
be used as the ultimate grading system for cancer 
aggressiveness. Each carcinoma has its own 
intrinsic malignancy.
Common epithelial carcinomas do not arise 
from mutations in specific oncogenes
The chronic phase of chronic myeloid leukemia
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(CML) reflects the master gene  BCR-ABL, and is 
another example of the master gene model of 
cancer development. BCR-ABL fusion protein 
formation presents the common initiation path-
way for cancer development in the CML chronic 
phase. The advent of the tyrosine kinase inhibi-
tor, imatinib, gave us the most optimistic view for 
its treatment. However, the constitutive activa-
tion of tyrosine kinase in blood cells sometimes 
itself leads to genomic instability and the accumu-
lation of secondary mutations on oncogenes, 
resulting in progression to advanced-stage CML, 
known as the accelerated stage and the blast 
stage. At this advanced stage, CML no longer 
shares the common pathway activated in blood 
cells. The cancer development mechanism of 
most common epithelial carcinomas is similar to 
that of the advanced-stage CML, which presents a 
challenge in cancer therapeutics because one 
cannot expect to stop cancer cell growth by 
blocking the common pathway of cell growth in 
one type of carcinoma. The genomic profile of one 
cancer varies from another and the oncogenes 
involved in carcinogenesis differs case by case, 
even in the same type of carcinoma. We must 
sometimes consider more than several pathways 
of cell growth advantage in one cancer.
How many oncogenes are left to be discovered 
by cancer genome study? 
 The first list of oncogenes came from studies of 
oncogenic viruses. Retroviruses, which have the 
potential to transform cells in vivo and in vitro, 
have the virus oncogenic sequences (v-onc), later 
those homologous equences were discovered in 
human cells and are called cellular oncogenes (c-
onc). In this article, an oncogene is simply defined 
as a gene in which a mutation gives its cell a 
growth  advantage—a definition that includes 
tumor suppressor genes and master genes. In 
cancer genome studies, the new definition of 
oncogene should include genes that mutate signifi-
cantly more often than would be expected at 
random in cancers. This definition for oncogenes 
would pick up genes that initially appear irrele-
vant to cell growth, such as those that encode 
olfactory receptors and the muscle protein titin 
(Lawrence et al. 2013). A deeper study of the 
gene products could reveal unexpected roles for 
these proteins, which may lead to their re-
classification into the classical ist of oncogenes (as 
defined in this article). Alternatively, another 
explanation of their higher mutation frequency in 
cancer might be found. In recent studies of lung
carcinoma, nearly all genes found to mutate at 
significant frequency have already been discov-
ered to be oncogenes (Vogelstein et al. 2013). 
However, even if a new master type oncogene is 
not discovered in cancer genome studies, function-
al studies of products of frequently mutated genes 
and identifying oncogenes (as alternately defined) 
is invaluable. A quantitative approach for carcin-
ogenesis by measuring the cell growth advantage 
from each driver mutation is essential, consid-
ering the mutational heterogeneity in common 
epithelial carcinoma.
Synergic growth  
mutation
advantage, high score driver
 According to classic epidemiologic studies, de-
velopment of ordinary solid tumors requires at 
least five to eight driver mutations. As discussed 
above, determining which mutation in a cancer 
genome is the driver mutation is difficult. If a non-
synonymous mutation appears in a well-docu-
mented site of an already identified oncogene, it 
can reasonably be supposed to be the driver muta-
tion. In other cases, determining if each mutation 
is a driver mutation is currently beyond our 
powers. The pediatric tumor medulloblastoma 
requires only eight non-synonymous mutations 
per tumor, as a median, among which, one to two 
mutations are considered to be driver mutations. 
Because only the exome of this cancer genome 
was sequenced, some driver mutations of medul-
loblastoma could have been missed. More critical-
ly, these  "one to two" driver mutations could be 
high score mutations in cancer development, in 
which their contribution per mutation to cell 
growth advantage is much greater than the aver-
age  contribution—conceivably almost equivalent 
to master gene mutations. The importance of 
analysis of low non-synonymous mutation tumors 
(such as acute myeloid leukemia, chronic lympho-
cytic leukemia, glioblastoma, neuroblastoma, me-
dulloblastoma, and rhabdoid tumor) cannot be 
overstated. However, the possibility of a synergic 
effect on cell growth by two or three mutations 
should not be ignored. Historically, the transfe-
ction of MYC combined with RAS transformed 
cultured fibroblasts in vitro.
Cancer therapeutics in the cancer genome era 
 In conventional cancer chemotherapy, the 
common features of cancer cells, such as faster 
cell division, DNA synthesis, and replication of 
normal cells, are targets of drugs, such as inhibi-
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tors of nucleic acid metabolism and DNA synthe-
sis, or blockers of cell division. Conventional 
drugs are effective for liquid tumors such as 
leukemia, and solid tumors of germ cell origin. 
However, on other types of cancer, especially 
common epithelial carcinomas, the effect is very 
limited. For master gene cancer such as chronic 
myeloid leukemia, specific inhibitors for master 
gene product have successfully opened a new 
stage for cancer therapeutics. However, consid-
ering the heterogeneity of common epithelial car-
cinomas, we cannot reasonably expect a master 
gene-specific approach for their therapies. In 
carcinoma, different sets of drugs may be needed 
to treat the same type of carcinoma (for example, 
esophageal squamous cell carcinoma). Tailor-
made chemotherapy for common epithelial carci-
nomas that depend on the type of driver muta-
tions could be the therapeutic choice in the cancer 
genome era.
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